TB-500

Price and cost-per-mg comparison

TB-500 is a synthetic peptide corresponding to residues 17–23 of thymosin beta-4 (Tb4), a 43-amino-acid protein with established roles in actin cytoskeleton regulation, wound healing, and tissue repair; no published studies have directly examined TB-500 as a compound in its own right. The Tb4 parent protein promotes actin sequestration and cell migration through beta-thymosin repeat interactions, and generates the anti-fibrotic tetrapeptide Ac-SDKP via enzymatic cleavage; TB-500 is hypothesized to retain a subset of these activities in a shorter, potentially more bioavailable fragment form. All available evidence for TB-500 derives from thymosin beta-4 and Ac-SDKP preclinical research, where animal studies demonstrate tissue-reparative and anti-fibrotic effects in cardiovascular, renal, and musculoskeletal models; human clinical translation has not been established for either the parent compound or the fragment. TB-500 has no FDA approval or regulatory approval in any jurisdiction; its hypothesized activity has not been validated in any published study using the fragment specifically, and it is available only as a research compound with a citation base derived entirely from parent-compound literature. TB-500 is commonly studied in combination with BPC-157 and GHK-Cu in what is referred to as the GLOW research blend, with the rationale that thymosin beta-4 fragment activity — actin sequestration and cell migration support — complements BPC-157's angiogenic properties. The GLOW combination is investigated in research contexts for synergistic tissue repair across musculoskeletal, connective tissue, and wound healing applications. TB-500 is most commonly administered via subcutaneous injection in research contexts, consistent with the injectable format used in Tb4 preclinical studies. Nasal spray delivery of TB-500 — often in combination with BPC-157 — has emerged as an investigational format in research blend products, offering a needle-free alternative for combination protocols; systemic bioavailability data for nasal TB-500 in humans is not established. The BPC-157 and TB-500 combination is among the most widely researched peptide stack pairings for tissue repair, with research rationale based on complementary signaling — BPC-157's angiogenic and nitric oxide pathway effects pairing with TB-500's actin cytoskeleton modulation and cell migration promotion. Preclinical research on this combination suggests additive or synergistic tissue-reparative effects across tendon, muscle, and wound healing models, though no human clinical trials have examined the combination directly. The GLOW blend adds GHK-Cu to this pairing, a three-compound combination studied in research contexts for complementary effects on collagen synthesis and anti-inflammatory signaling. [Women's health addendum] No human trial data exist for injectable TB-500 in any women's-health indication. Human RCT data for thymosin β4 exist only for the distinct ophthalmic candidate RGN-259, which does not validate injectable TB-500's safety or efficacy for any use. TB-500 shares BPC-157's angiogenesis-mediated theoretical tumor-promotion concern from preclinical mechanistic data. TB-500/thymosin β4 is WADA-prohibited at all times (S2.3, Growth Factors, since 2018) and has no FDA approval.

146 listings · 73 vendors · updated 28 Sept 2026 · how prices are computed · educational only, not medical advice